MetLife Investment Management’s Aura Biosciences AURA Stock Holding History

MetLife Investment Management’s Portfolio AURA Stock Details AURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$167K	Sell	24,962 -69	-0.3%	-$396	﹤0.01%	2316
2025 Q4	$136K	Buy	25,031 +5,674	+29%	+$33.7K	﹤0.01%	2461
2025 Q3	$120K	Sell	19,357 -7,980	-29%	-$52.2K	﹤0.01%	2575
2025 Q2	$171K	Hold	27,337	–	–	﹤0.01%	2268
2025 Q1	$160K	Sell	27,337 -448	-2%	-$3.39K	﹤0.01%	2309
2024 Q4	$228K	Hold	27,785	–	–	﹤0.01%	2239
2024 Q3	$248K	Hold	27,785	–	–	﹤0.01%	2172
2024 Q2	$210K	Buy	27,785 +11,076	+66%	+$81.1K	﹤0.01%	2209
2024 Q1	$131K	Buy	16,709 +1,733	+12%	+$14.4K	﹤0.01%	2413
2023 Q4	$133K	Hold	14,976	–	–	﹤0.01%	2468
2023 Q3	$134K	Hold	14,976	–	–	﹤0.01%	2428
2023 Q2	$185K	Buy	14,976 +3,950	+36%	+$42.2K	﹤0.01%	2331
2023 Q1	$102K	Hold	11,026	–	–	﹤0.01%	2544
2022 Q4	$116K	Hold	11,026	–	–	﹤0.01%	2533
2022 Q3	$200K	Hold	11,026	–	–	﹤0.01%	2306
2022 Q2	$156K	Buy	+11,026	New	+$182K	﹤0.01%	2470

Other funds holding AURA

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MetLife Investment Management's AURA Position: Q1 2026 in Review

MetLife Investment Management reduced its Aura Biosciences (AURA) stake by 0.28% in Q1 2026, selling an estimated $396 and leaving 24,962 shares worth $167K. The position accounts for ﹤0.01% of the portfolio, ranked #2316.

MetLife Investment Management first reported a position in AURA in Q2 2022 and has held it in 16 quarters since. The position peaked at $248K in Q3 2024. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

MetLife Investment Management held 24,962 shares of Aura Biosciences worth $167K as of Q1 2026.
MetLife Investment Management sold 69 Aura Biosciences shares in Q1 2026, an estimated $396.
Aura Biosciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2316 holding.
MetLife Investment Management first reported a position in Aura Biosciences in Q2 2022 and has held it in 16 quarters since.
MetLife Investment Management's Aura Biosciences position peaked at $248K in Q3 2024.
126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.